Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial
- 2 August 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 6 (9), 691-698
- https://doi.org/10.1016/s2213-2600(18)30177-2
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trialTrials, 2012
- Acute Respiratory Distress SyndromeJAMA, 2012
- Asthma phenotypes: the evolution from clinical to molecular approachesNature Medicine, 2012
- Pharmacological treatments for acute respiratory distress syndromeCurrent Opinion in Critical Care, 2010
- Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy VolunteersAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Incidence and Outcomes of Acute Lung InjuryThe New England Journal of Medicine, 2005
- Higher versus Lower Positive End-Expiratory Pressures in Patients with the Acute Respiratory Distress SyndromeThe New England Journal of Medicine, 2004
- Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problemsStatistics in Medicine, 2002
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeThe New England Journal of Medicine, 2000
- The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.American Journal of Respiratory and Critical Care Medicine, 1994